Related Experiment Videos
Effect of prophylactic phenobarbital on intraventricular hemorrhage in high-risk infants
Insights
Phenobarbital did not affect the incidence of subependymal-intraventricular hemorrhage in premature infants. However, it may reduce the severity of these brain bleeds, offering a potential benefit for neonates.
Area of Science:
- Neonatal Medicine
- Pediatric Neurology
- Pharmacology
Background:
- Subependymal-intraventricular hemorrhage (SEH-IVH) is a serious complication in premature infants.
- Phenobarbital is a medication with potential neuroprotective properties.
Purpose of the Study:
- To investigate the effect of phenobarbital on the incidence and severity of SEH-IVH in premature neonates.
- To assess the safety and efficacy of phenobarbital in this vulnerable population.
Main Methods:
- A randomized controlled trial involving 42 premature infants under 24 hours of age.
- Infants were assigned to either a control group or a phenobarbital treatment group.
- Phenobarbital was administered with loading and maintenance doses over 6 days, with serial echoencephalograms for monitoring.
Main Results:
- The incidence of SEH-IVH was similar in both phenobarbital-treated and control groups (48% each).
- Hemorrhages in the phenobarbital group were significantly less severe than in the control group.
- Phenobarbital-treated infants who experienced hemorrhage were larger and more mature than control infants who bled.
Conclusions:
- Phenobarbital does not appear to reduce the incidence of subependymal-intraventricular hemorrhage in premature infants.
- Phenobarbital may offer a beneficial effect in reducing the severity of SEH-IVH.
- Further research is warranted to explore phenobarbital's role in managing neonatal brain bleeds.
Abstract:
Forty-two premature infants less than 24 hours of age, with normal admission echoencephalograms, were randomly assigned to control or phenobarbital treatment groups. Infants in the treated group received two loading doses of 10 mg/kg of phenobarbital 12 hours apart, followed by a maintenance dose of 2.5 mg/kg every 12 hours for 6 days. Serial echoencephalograms were obtained in both groups. The groups were comparable with regard to birth weight, gestational age, and potential risk factors for subependymal-intraventricular hemorrhage. Ten infants (48%) in each group developed hemorrhage. The hemorrhages in the phenobarbital-treated group were significantly less severe than those in the control group. The phenobarbital-treated infants who bled, however, were also significantly larger and more mature than control infants who bled. The results of this study indicate no effect of phenobarbital on the incidence of subependymal-intraventricular hemorrhage, but a possible beneficial effect on the severity of hemorrhage.